AstraZeneca (NYSE: AZN) today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE